How Lysosomes Keep Us Healthy
| Lysosomes; Lysosomal storage diseases; Enzyme replacement therapy; Substrate reduction therapy; Gene therapy;
| Flunkert S, Hirschmugl T
| 2023
| Frontiers for Young Minds
|
10.3389/frym.2023.1109280
|
In vitro assessment of dietary bioactives for TFEB activation as a possible target to support cognitive and emotional wellbeing
| TFEB; Spermidine; Curcumin; Docosahexaenoic acid; Ellagic acid; Astrocytes; Mood disorders
| Trovo L, Vaucher A, Pan Y, Steiner P, Flunkert S, Fleming SA, Preitner N
| 2023
| Journal of Functional Foods
|
10.1016/j.jff.2023.105855
|
Evaluation of Neuropathological Features in the SOD1-G93A Low Copy Number Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.
| Body weight; Muscle phenotype; Muscle strength; Neuroinflammation; Spinal cord; Survival rate.
| Molnar-Kasza A, Hinteregger B, Neddens J, Rabl R, Flunkert S, Hutter-Paier B
| 2021
| Frontiers in Molecular Neuroscience
|
PMID: 34248499
|
Homozygosity of BACHD rats not only causes strong behavioral deficits in young female rats but also a reduced breeding success.
| Behavioral analysis; Breeding success; Homozygosity; Huntington’s disease; Learning and memory; Sex differences.
| Kurat S, Heinrich P, Molnar-Kasza A, Loeffler T, Flunkert S, Hutter-Paier B
| 2021
| Brain Research
|
PMID: 33662341
|
Constant Levels of Tau Phosphorylation in the Brain of htau Mice.
| Alzheimer’s disease; Genetic background; Human tau; Immunofluorescent labelling; Mouse model; Phosphorylation; Progression; Tauopathies.
| Neddens J, Daurer M, Loeffler T, Alzola Aldamizetxebarria S, Flunkert S, Hutter-Paier B
| 2020
| Frontiers in Molecular Neuroscience
|
PMID: 3298268
|
Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models.
| Mouse Models; Hippocampus; Genetically modified animals; Phosphorylation; Alzheimer’s disease; Occipital lobe; Dementia
| Neddens J, Daurer M, Flunkert S, Beutl K, Loeffler T, Walker L, Attems J, Hutter-Paier B
| 2020
| PLoS One
|
PMID: 32645028
|
Neurofilament-Light Chain as Biomarker of Neurodegenerative and Rare Diseases With High Translational Value.
| Neurofilament-light chain; Animal model; Biomarker; Cerebrospinal fluid; Lysosomal storage diseases; Neurodegenerative disease; Plasma; Preclinical research
| Loeffler T, Schilcher I, Flunkert S, Hutter-Paier B
| 2020
| Frontiers in Neuroscience
|
PMID: 32595447
|
Characterization of the visceral and neuronal phenotype of 4L/PS-NA mice modeling Gaucher disease.
| Mouse models; Cerebellum; Body weight; Hippocampus; Spleen; Thymus; Macrophages; White blood cells
| Schiffer V, Santiago-Mujika E, Flunkert S, Schmidt S, Farcher M, Loeffler T, Schilcher I, Posch M, Neddens J, Sun Y, Kehr J, Hutter-Paier B
| 2020
| PLoS One
|
PMID: 31929594
|
Hepatic and neuronal phenotype of NPC1-/- mice.
| Cell biology; Molecular biology; Neuroscience; Physiology
| Santiago-Mujica E, Flunkert S, Rabl R, Neddens J, Loeffler T, Hutter-Paier B
| 2019
| Heliyon
|
PMID: 30923761
|
Phosphorylation of different tau sites during progression of Alzheimer’s disease.
| Cingulate; Frontal; Immunofluorescent labeling; Microtubule-associated protein tau; Occipital and temporal cortex; Phosphorylation; Transentorhinal region
| Neddens J, Temmel M, Flunkert S, Kerschbaumer B, Hoeller C, Loeffler T, Niederkofler V, Daum G, Attems J, Hutter-Paier B
| 2018
| Acta Neuropathologica Communications
|
PMID: 29958544
|
SEN1500, a novel oral amyloid-β aggregation inhibitor, attenuates brain pathology in a mouse model of Alzheimer’s disease.
| Activated microglia; Aggregation inhibitor; Amyloid-β; Pharmacotherapy; Plaques; SEN1500
| Brunner D, Flunkert S, Neddens J, Duller S, Scopes DIC, Treherne JM, Hutter-Paier B
| 2017
| Neuroscience Letters
|
PMID: 28917978
|
Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
| Memory deficits; Motor deficits; Parkinson’s disease; Protein expression; Synucleinopathies; α-Synuclein
| Rabl R, Breitschaedel C, Flunkert S, Duller S, Amschl D, Neddens J, Niederkofler V, Rockenstein E, Masliah E, Roemer H, Hutter-Paier B
| 2017
| BMC Neuroscience
|
PMID: 28143405
|
Quantitative evaluation of orofacial motor function in mice: The pasta gnawing test, a voluntary and stress-free behavior test.
| Amyotrophic lateral sclerosis; Neurodegenerative disease; Niemann-Pick disease; Parkinson’s disease; TDP-43; α-synuclein
| Rabl R, Horvath A, Breitschaedel C, Flunkert S, Roemer H, Hutter-Paier B
| 2016
| Journal of Neuroscience Methods
|
PMID:27746230
|
Neuroinflammation and related neuropathologies in APPPSL mice: further values of this in vivo model of Alzheimer’s disease.
| Hippocampus; Cortex, Alzheimer’s disease; Lipid peroxidation; Amyloid-beta; Aggregation
| Loeffler T, Flunkert S, Havas D, Schweinzer C, Uger M, Windisch M, Steyrer E, Hutter-Paier B
| 2014
| Journal of Neuroinflammation
|
PMID: 24886182
|
Commentary to the recently published review „Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer’s disease” by Li, Evrahimi and Schluesener.
| APP; Alzheimer’s disease; Animal models; Drug trials; Tau
| Windisch M, Flunkert S, Havas D, Hutter-Paier B
| 2013
| Ageing Research Reviews
|
PMID: 23851053
|
Time course and progression of wild type α-Synuclein accumulation in a transgenic mouse model.
| Parkinson’s disease; Motor deficits; Phosphorylation; Limbic system; GABAergic interneurons; Glutamatergic principal cells; Ventricular zone; Rostral migratory stream
| Amschl D, Neddens J, Havas D, Flunkert S, Rabl R, Roemer H, Rockenstein E, Masliah E, Windisch M, Hutter-Paier B
| 2013
| BMC Neuroscience
|
PMID: 23302418
|
Elevated Levels of Soluble Total and Hyperphosphorylated Tau Result in Early Behavioral Deficits and Distinct Changes in Brain Pathology in a New Tau Transgenic Mouse Model.
| Memory deficits; Phosphorylation; Tau; Tauopathy; Transgenic mouse model
| Flunkert S, Hierzer M, Loeffler T, Rabl R, Neddens J, Duller S, Schofield EL, Ward MA, Posch M, Jungwirth H, Windisch M, Hutter-Paier B
| 2012
| Neurodegenerative Diseases
|
PMID: 22797329
|
Stable mutated tau441 transfected SH-SY5Y cells as screening tool for Alzheimer’s disease drug candidates.
| Phosphorylation; Tau; in vitro; SH-SY5Y cells; Kinase inhibitor; Mass spectrometry
| Loeffler T, Flunkert S, Taub N, Schofield EL, Ward MA, Windisch M, Hutter-Paier B
| 2012
| Journal of Molecular Neuroscience
|
PMID: 22351109
|
